Editing Novartis (section)

===Consumer health===
{{div col|colwidth=22em}}
* [[Benefiber]]
* [[Bialcol]] Alcohol
* [[Buckley's]] cold and cough formula
* [[Bufferin]]
* [[ChestEze]]
* [[Comtrex]] cold and cough
* [[Penciclovir|Denavir/Vectavir]]
* [[Miconazole|Desenex]]
* [[Doan's]] pain relief
* [[Ex-Lax]]
* [[Excedrin]]
* [[Fenistil]]
* [[Gas-X]]
* [[Habitrol]]
* [[Keri]] skin care
* [[Lamisil]] foot care
* [[Lipactin]] [[Herpes simplex|herpes]] symptomatic treatment
* [[Maalox]]
* [[Nicotine replacement therapy|Nicotinell]]
* [[No-doz]]
* [[Quinvaxem]] ([[DTwP-HepB-Hib vaccine|Pentavalent vaccine]])
* [[Xylometazoline|Otrivine]]
* [[Lansoprazole|Prevacid 24HR]]
* [[Savlon]]
* [[Tavist]]
* [[Theraflu]]
* [[Tioconazole|Vagistat]]
* Tixylix
* [[Diclofenac|Voltaren]]
{{div col end}}

In January 2009, the [[United States Department of Health and Human Services]] awarded Novartis a $486&nbsp;million contract for construction of the first US plant to produce cell-based [[influenza vaccine]], to be located in [[Holly Springs, North Carolina]]. The stated goal of this program is the capability of producing 150,000,000 doses of [[Influenza research#Pandemic flu vaccine planning|pandemic vaccine]] within six months of declaring a flu pandemic.<ref>{{Cite press release |title=US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine |date=15 January 2009 |publisher=Novartis |url=http://www.novartis.com/newsroom/media-releases/en/2009/1282432.shtml |access-date=2009-11-13 |archive-url=https://web.archive.org/web/20100603115944/http://www.novartis.com/newsroom/media-releases/en/2009/1282432.shtml |archive-date=2010-06-03 |url-status=dead}}</ref>

In April 2014, Novartis divested its consumer health section with $3.5&nbsp;billion worth of assets into a new joint venture with [[GlaxoSmithKline]], named GSK Consumer Healthcare, of which Novartis will hold a 36.5% stake.<ref>{{Cite web |last=Staton |first=Tracy |date=2014-04-22 |title=Novartis, GSK team up in consumer JV to save big money, gain big scale |url=http://www.fiercepharma.com/m-a/novartis-gsk-team-up-consumer-jv-to-save-big-money-gain-big-scale |access-date=2016-05-16 |website=FiercePharma |publisher=Questex Media Group |archive-date=26 October 2020 |archive-url=https://web.archive.org/web/20201026075857/https://www.fiercepharma.com/m-a/novartis-gsk-team-up-consumer-jv-to-save-big-money-gain-big-scale |url-status=live }}</ref> In March 2018, GSK announced that it has reached an agreement with Novartis to acquire Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13&nbsp;billion (£9.2&nbsp;billion).<ref name=":1" />